Fortune February 4, 2020
When Andreessen Horowitz pours money into an industry, word tends to get around. So when the venture capital giant pours $750 million into a single sector, you really know that something big is going on.
On Tuesday, Andreessen announced a third iteration of its biopharmaceutical and digital health fund, dubbed simply “Bio Fund III.” The firm used aspirational language to describe its ambitions and promote what is literally a three-quarters of a billion dollar fund.
“Software is now affecting not just how we do not just one thing—cloning DNA, or engineering genes—but how we do it all across the board, blurring lines, breaking down traditional silos, changing our processes and business models,”...